Disordered phosphorus and vitamin D metabolism are novel risk factors for cardiovascular disease (CVD) and mortality in patients with chronic kidney disease (CKD), a public health epidemic estimated to affect 20 million people in the US. Fibroblast growth factor-23 (FGF-23) is a recently discovered hormone that regulates serum phosphate and 1, 25-dihydroxyvitamin D (1,25D) levels. The most common disorder of FGF-23 excess is CKD in which progressive, severe increases help maintain normophosphatemia despite declining nephron mass. Preliminary data from our group suggest that increased FGF-23 levels in normophosphatemic CKD patients are also associated with coronary artery calcification, left ventricular hypertrophy, and mortality. Importantly, FGF-23 levels rise long before hyperphosphatemia first develops and can be lowered with routine clinical interventions such as dietary phosphorus restriction and phosphorus binders. Thus, we hypothesize that FGF-23 excess is a modifiable risk factor for adverse outcomes in CKD and a novel biomarker to help guide phosphate reduction strategies in normophosphatemic CKD patients who are not currently treated. Our experienced investigative team will study FGF-23 excess as a novel risk factor for adverse cardiovascular and renal outcomes in the Chronic Renal Insufficiency Cohort, an NIH-supported prospective study of 3800 predialysis CKD patients, the vast majority of whom have normal serum phosphate levels. The results could suggest a major paradigm shift for clinical practice with public health implications: phosphate reduction strategies for far more people far earlier in their course of CKD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK081374-04
Application #
8141996
Study Section
Special Emphasis Panel (ZDK1-GRB-N (M3))
Program Officer
Kimmel, Paul
Project Start
2008-09-25
Project End
2012-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
4
Fiscal Year
2011
Total Cost
$464,978
Indirect Cost
Name
University of Miami School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Scialla, Julia J; Asplin, John; Dobre, Mirela et al. (2017) Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes. Kidney Int 91:204-215
Mehta, Rupal; Cai, Xuan; Hodakowski, Alexander et al. (2017) Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol 12:1795-1803
Middleton, John P; Wolf, Myles (2017) Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic. JAMA 317:139-141
Batacchi, Zona; Robinson-Cohen, Cassianne; Hoofnagle, Andrew N et al. (2017) Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD. Clin J Am Soc Nephrol 12:1498-1506
Munoz Mendoza, Jair; Isakova, Tamara; Cai, Xuan et al. (2017) Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 91:711-719
Gutiérrez, Orlando M; Parsa, Afshin; Isakova, Tamara et al. (2016) Genetic African Ancestry and Markers of Mineral Metabolism in CKD. Clin J Am Soc Nephrol 11:653-62
Mehta, Rupal; Cai, Xuan; Lee, Jungwha et al. (2016) Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol 1:548-56
Lash, James P; Ricardo, Ana C; Roy, Jason et al. (2016) Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies. Am J Kidney Dis 68:545-553
Bansal, Nisha; Xie, Dawei; Tao, Kelvin et al. (2016) Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol 11:1189-96
Wolf, Myles; Mehta, Rupal (2015) Fibroblast Growth Factor-23 Fans the Flames of Heart and Kidney Failure. JACC Heart Fail 3:840-2

Showing the most recent 10 out of 66 publications